A Phase 3 interventional study of Neuronox and Botox in Essential Blepharospasm, sponsored by Medy-Tox. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-13.
Sponsored by Medy-Tox · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical study evaluates the efficacy and safety of Neuronox compared with Botox in adults with essential blepharospasm.
Subjects are randomly assigned into the two groups at the ratio of 1:1. The purpose of study is to confirm the non-inferiority of Neuronox to Botox in terms of the efficacy and safety in subjects with essential blepharospasm.
Medy-Tox is the lead sponsor of 49 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Botulinum Toxin Type A for injection
Drug: Neuronox
Botulinum Toxin Type A for injection
Drug: Botox
JRS (Jankovic Rating Scale) sum-score
Change from baseline at 4 week for the JRS (Jankovic Rating Scale) sum-score
Time frame: From baseline at 4 week
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2016 to primary completion in Mar 2017, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
Benign essential blepharospasm